Is MPS Pharmaa overvalued or undervalued?

As of November 12, 2024, MPS Pharmaa is considered risky and overvalued with a PE ratio of -5.22 and an EV to EBITDA of -2.59, indicating severe operational challenges and inefficiencies, despite a significant 666.67% return over the past five years, which is unsustainable compared to the Sensex's 211.54% return.

As of 12 November 2024, MPS Pharmaa's valuation grade has moved from does not qualify to risky, indicating a significant shift in its perceived financial health. The company is currently deemed overvalued, with a PE ratio of -5.22 and an EV to EBITDA of -2.59, both of which suggest severe operational challenges. Additionally, the ROCE stands at -48.75%, highlighting inefficiencies in capital utilization.<BR><BR>When compared to peers, MPS Pharmaa's metrics are starkly unfavorable. For instance, MMTC, also categorized as risky, has a PE ratio of 119.39, while Optiemus Infra, which is fairly valued, boasts a PE of 82.35. Notably, MPS Pharmaa's PEG ratio is 0.00, indicating no expected growth, further reinforcing its overvaluation status. Despite a remarkable 666.67% return over the past five years, this performance contrasts sharply with the broader market, as evidenced by the Sensex's 211.54% return over the same period, suggesting that MPS Pharmaa's current price may not be sustainable given its financial metrics.

What is the technical trend for MPS Pharmaa?

As of May 27, 2025, MPS Pharmaa shows a mildly bullish trend in daily moving averages, but longer-term indicators like weekly and monthly MACD, KST, and Bollinger Bands suggest a mixed outlook with bearish signals.

As of 27 May 2025, the technical trend for MPS Pharmaa has changed from mildly bearish to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly and monthly MACD and KST remain mildly bearish. The Bollinger Bands reflect a mildly bearish trend on the weekly and bearish on the monthly. The Dow Theory shows no trend on the weekly and mildly bearish on the monthly. Overall, the current technical stance is mildly bullish, but the strength is tempered by bearish signals in longer time frames.

Who are in the management team of MPS Pharmaa?

As of March 2019, the management team of MPS Pharmaa includes Peeyush Kumar Aggarwal (Managing Director), Manoj Kumar Jain and Madhu Sharma (Independent Directors), Pooja Chuni (Company Secretary), and Ram Niwas Sharma (Director). They are responsible for the company's governance and operations.

As of March 2019, the management team of MPS Pharmaa includes the following individuals:<BR><BR>1. Peeyush Kumar Aggarwal - Managing Director<BR>2. Manoj Kumar Jain - Independent Director<BR>3. Pooja Chuni - Company Secretary<BR>4. Madhu Sharma - Independent Director<BR>5. Ram Niwas Sharma - Director<BR><BR>These members play key roles in the governance and operations of the company.

What does MPS Pharmaa do?

MPS Pharmaa Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology sector, focusing on ethical, generic, and over-the-counter drugs. As of September 2024, it reported a net profit of -2 Cr and has a market cap of INR 6 Cr.

Overview:<BR>MPS Pharmaa Ltd operates in the Pharmaceuticals & Biotechnology industry as a micro-cap company, focusing on the development and production of ethical, generic, and over-the-counter drugs.<BR><BR>History:<BR>MPS Pharmaa Ltd was established with the goal of achieving USFDA standards of quality. The latest quarterly results reported are for September 2024, indicating a net profit status.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: -2 Cr (Quarterly Results - Sep 2024)<BR>Market-cap value: INR 6 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A (Loss Making)<BR>Industry P/E: 27<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 3.69<BR>Return on Equity: -51.30%<BR>Price-to-Book: 2.92<BR><BR>Contact Details:<BR>Address: 138 Roz-Ka-Meo Industrial Area, Sohna Mewat Haryana : 122103<BR>Tel: 91-124-2362471/2014471<BR>Email: mail@advikindia.com<BR>Website: http://www.mpspharmaa.com

Who are the top shareholders of the MPS Pharmaa?

The top shareholders of MPS Pharmaa are Omkam Pharmaceuticals Private Limited with 25.65%, Pataliputra International Limited at 17.51%, and individual investors holding a combined 36.05%. There are currently no mutual funds or foreign institutional investors involved.

The top shareholders of MPS Pharmaa include Omkam Pharmaceuticals Private Limited, which holds the largest share at 25.65%. Following that, Pataliputra International Limited is the highest public shareholder with a stake of 17.51%. Additionally, individual investors collectively hold 36.05% of the shares. Notably, there are no mutual funds or foreign institutional investors currently holding shares in the company.

Should I buy, sell or hold MPS Pharmaa?

How has been the historical performance of MPS Pharmaa?

MPS Pharmaa has experienced a consistent decline in financial performance from 2020 to 2025, with worsening reserves, decreasing shareholder funds, and negative profit before tax in multiple years, indicating ongoing operational and liquidity challenges. The book value per share fell from Rs 4.38 in 2020 to Rs 0.57 in 2025.

Answer:<BR>The historical performance of MPS Pharmaa shows a consistent decline in key financial metrics over the years, particularly from 2020 to 2025.<BR><BR>Breakdown:<BR>MPS Pharmaa's share capital has remained stable at Rs 19.11 crore from 2020 to 2025, while total reserves have worsened, moving from -10.75 crore in 2020 to -18.03 crore in 2025. Shareholder's funds have also decreased significantly, dropping from Rs 8.36 crore in 2020 to just Rs 1.08 crore in 2025. The company has maintained no long-term borrowings throughout this period, indicating a lack of debt financing. However, total liabilities have decreased from Rs 16.41 crore in 2020 to Rs 9.33 crore in 2025, primarily due to a reduction in current liabilities. The total assets have similarly declined from Rs 16.41 crore in 2020 to Rs 9.33 crore in 2025, with a notable drop in net current assets, which have remained negative, indicating ongoing liquidity issues. The book value per share has also fallen from Rs 4.38 in 2020 to Rs 0.57 in 2025, reflecting the company's deteriorating financial health. Profit before tax has been negative in several years, with a loss of Rs 1 crore in 2023 and Rs 4 crore in 2021, while cash flow from operating activities has consistently been zero or negative, highlighting ongoing operational challenges.

When is the next results date for MPS Pharmaa?

The next results date for MPS Pharmaa is 14 November 2025.

The next results date for MPS Pharmaa is scheduled for 14 November 2025.

Why is MPS Pharmaa falling/rising?

As of 13-Nov, MPS Pharmaa Ltd's stock price is flat at Rs. 2.08, having hit a new 52-week low and underperforming its sector by 27.04%. Despite a strong long-term performance, recent trading patterns and a significant drop in investor participation indicate current struggles.

As of 13-Nov, MPS Pharmaa Ltd's stock price is flat at Rs. 2.08, with no change in percentage terms (0.00%). The stock has hit a new 52-week low today, indicating a significant decline in value. It has underperformed its sector by 27.04% and has shown erratic trading patterns, not trading on 5 out of the last 20 days. Additionally, investor participation has decreased sharply, with delivery volume dropping by 98.17% compared to the 5-day average. The stock's moving averages indicate that it is currently lower than the 5-day, 20-day, 50-day, and 100-day moving averages, although it remains higher than the 200-day moving average. There is no information available regarding positive or negative factors affecting the stock.<BR><BR>Broader market context shows that the Sensex has increased by 1.40% over the past week and 2.61% over the past month, while MPS Pharmaa's specific return data for these periods is not available. However, over the last five years, MPS Pharmaa has significantly outperformed the benchmark with a return of 477.78% compared to the Sensex's 94.46%. This stark contrast suggests that while the broader market is experiencing growth, MPS Pharmaa is currently struggling, as evidenced by its recent price movements and declining investor interest.

Which are the latest news on MPS Pharmaa?